AGP Executive Report
Last update: 10 hours agoGLP-1 Coverage Shift: CMS will launch a temporary “GLP-1 Bridge” Medicare demo starting July 1, letting eligible beneficiaries pay $50/month for certain weight-loss drugs, while keeping the underlying federal ban on routine coverage in place. Cancer Risk Watch: New research and conference reports are exploring whether GLP-1 drugs may lower cancer risk, but experts stress there’s not enough proof to use them for cancer prevention alone. FDA Supply Alert: The FDA says stereotactic breast biopsy needle shortages are expected to last until March 2027 due to a Hologic recall tied to particle risk, urging hospitals to conserve inventory and prioritize high-risk patients. Accessibility Deadline: HHS compliance rules require accessible exam tables and weight scales by July 8, with web/mobile accessibility timelines following in 2027–2028. Maternal Health: UW Medicine-led research links chronic stress in late pregnancy to reduced fetal iron uptake (up to ~15%), with stronger effects in male fetuses. Equity in Care: A NEJM commentary highlights practical steps to identify and counter implicit bias in diagnosis and treatment. Neonatal Treatment Update: A large NEJM trial finds no benefit—and more serious newborn adverse events—for adding erythropoietin to standard cooling therapy in birth asphyxia.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
